Evotec Se · XETR:EVT
Evotec — Investor Presentation (August 2024)
31 slides from Evotec's investor presentation, August 2024
Slide 1: General company presentation
General company presentation Evotec SE, Company presentation, August 2024
Slide 2: Disclaimer
Disclaimer This presentation (including any information which has been or may be supplied in writing or orally in connection herewith or in connection with any further inquiries) is being delivered on behalf of Evotec SE (the “Company”, “we,” “our” or “us”). This presentation is made pursuant to Sec
Slide 3: Together for Medicines that Matter
1 Together for Medicines that Matter 2 Shared R&D 3 Just – Evotec Biologics 4 Financials PAGE 3
Slide 4: Accelerating medicines that matter
Accelerating medicines that matter About us 4,000++ scientists Co-creating pipelines empowering our partners Leveraging our assets, targets or proprietary platforms for licensing, Across all disciplines and disease areas from co-development or potential NewCo creation, frequently combining target to
Slide 5: Leveraging the power of trust and collaboration in attractive markets
Leveraging the power of trust and collaboration in attractive markets Sharing as basis for success Shared R&D Biologics >500 CAGR 12% 30 80 >90% 25 2x 60 in USDbn in USDbn 20 partners working 15 40 10 in parallel on our 5 repeat business 20 platform 0 0 2022 2030 2022 2030 R&D outsourcing Continuous
Slide 6: Scientific AND operational excellence are both essential for our success
Scientific AND operational excellence are both essential for our success Benefits of increased emphasis on Operational excellence Shared R&D – From target to patient Discovery of next generation drugs with higher efficacy and probability of success. PanOmics approach for molecular disease understand
Slide 7: Shared R&D – Discovery of next generation drugs
Shared R&D – Discovery of next generation drugs with higher efficacy and probability of success PAGE 7
Slide 8: Comprehensive integrated research and development
Comprehensive integrated research and development Illustrative functional capabilities of the End-to-End shared R&D continuum From Target… …to Patient • PanOmics • E.MPD • E.IPSC • Predictive • Translational • Commercial API safety biology, biomarkers and drug product • Disease area • Structural • E
Slide 9: It all starts with precise patient data – From human to human
It all starts with precise patient data – From human to human Portfolio of Evotec Molecular Patient Databases (E.MPD) Therapeutic area Patients Chronic kidney 12,000 diseases (CKD) Kidney diseases Immune mediated 3,000 diseases Metabolic & Liver disease Inflammation Fibrosis Metabolic diseases 2,000
Slide 10: Paving the way towards increased clinical success
Paving the way towards increased clinical success Overview of PanOmics drug discovery platform EVOgnostic E.MPD PanOmics and AI-driven Unique database for patient stratification and patient data biomarker discovery Hit Lead Pre-clinical Clinical Sourcing novel ideas Target ID / validation Approval M
Slide 11: Multiple options for pipeline co-creation together with our partners
Multiple options for pipeline co-creation together with our partners >140 co-owned projects Inflammation & Neuroscience & pain Oncology Metabolic diseases Immunology1 Virology, Anti-bacterial & Global health Approved Jingxin SK Bio PhIII PhII Carrick Carrick Carrick Carrick Sernova Topas Clinical Ce
Slide 12: Just – Evotec Biologics
Just – Evotec Biologics Design and application of innovative technologies from discovery to commercial supply to dramatically expand global access to biotherapeutics Paradigm shift in biologics PAGE 12
Slide 13: JUST is addressing global access by alleviating major pain points
JUST is addressing global access by alleviating major pain points Key advantages of biologics manufacturing with Just – Evotec Biologics Facility building costs, US$m Lower COGs potential US$/g Traditional ~800 – Facility 1,000 Top-quartile -70- facility J.POD® - 250 80% J.POD® >50% Time to set up f
Slide 14: New options to cure Rare Diseases
New options to cure Rare Diseases Underserved indications 50% 30 million people of the people affected by 1. High titer cell lines in Europe are living rare diseases are children with rare disease 2. Rapid turn around 7,000 30 Product A 2 days million people rare disease & Product B disorders in US
Slide 15: Portfolio advancing towards clinical & commercial manufacturing
Portfolio advancing towards clinical & commercial manufacturing High level longitudinal portfolio overview: Just – Evotec Biologics Selected by U.S. Department of Defense for Manufacturing More than Technology Optimisation Programm 150 biologics ‘touched’ Partnerships Molecules in New partnerships i
Slide 16: Our continuous platform will even further excel with complex biologics
Our continuous platform will even further excel with complex biologics Trends in global biologics pipelines Size of global pipeline by therapeutic modality Share of complex Number of products1, from Phase I to III biologics in the pipeline 4,000 3,000 >40% Share of complex / unstable biologics rapid
Slide 17: Significant business expansion with commercial manufacturing
Significant business expansion with commercial manufacturing Closed Sales, in € m >1,000 ~900 >> 10x 3x >100 Dec 2021 Dec 2022 Dec 2023 Mar 2024 June 2024 July 2024 PAGE 17
Slide 18: Financials
Financials PAGE 18
Slide 19: Navigating in challenging markets
Navigating in challenging markets Condensed income statement 2023 – Evotec SE and subsidiaries in € m1 2023 2022 Change Comment • Cyber-related impact (especially Revenues 781.4 751.4 4% Development and Cyprotex) of which Just – Evotec Biologics (JEB) 108.4 51.3 >110% • Challenging markets (esp. bio
Slide 20: Guidance 2024
Guidance 2024 Guidance 20241 YE 2023 Comment Strong growth of JEB; Group revenues € 790 - 820 m € 781.4 m Soft market environment in Shared R&D Focus on scalable first-in-class R&D expenditure2 € 50 - 60 m € 64.8 m platforms and projects, safeguarding sustainable growth High fixed costs base; balanc
Slide 21: Three pillars towards profitable growth
Three pillars towards profitable growth Priority reset – Update (mid August 2024) Portfolio Capacity & 1 adjustments 2 External spend 3 Footprint • Exit Gene Therapy • First reduction in force • Site exits (Orth, Halle, & concluded (100 roles); U.S. Marcy) • Scale back API capacity and UK done • Ham
Slide 22: Looking ahead
Looking ahead Strategic review & accelerated transformation underway (illustrative) Leverage through revenue growth - faster than market Productivity levers Annualised savings: > € 40 m Footprint Priority Reset Capacity & external spend Portfolio adjustments // // - - 2024 2025 2026+ PAGE 22
Slide 23: Upcoming important dates
Upcoming important dates Financial calendar 2024 Commerzbank & ODDO BHF Corporate Conference 2023, Frankfurt/Main 03 September 2024 Morgan Stanley 21st Annual Global Healthcare Conference, New York 05 September 2024 Royal Bank of Canada CDMO Conference, virtual 23 September 2024 Berenberg Goldman Sa
Slide 24: Appendix
Appendix PAGE 24
Slide 25: Experienced management team with long-term mission
Experienced management team with long-term mission The management team Experience Experience Experience • 2017 – 2022 CEO of Mediq • 2021-2023: • 2002-2022: • 2005 – 2017 Various Global CFO of Wavin McKinsey & Company leadership positions at Linde • 2018-2021: Divisional • Significant exposure to th
Slide 26: Global view and deep experience for best governance
Global view and deep experience for best governance Independent and diverse Supervisory Board • Since 2014 Member of • Since 2019 Member of the • Since 2022 Member of Evotec’s Evotec’s Supervisory Board Supervisory Board Supervisory Board (2021 Chairperson) (2021 Vice Chair Person) • Since 2013, Dif
Slide 27: Sustainable growth enabled by commitment, culture, values & people
Sustainable growth enabled by commitment, culture, values & people Sustainability at Evotec Our People Our Partners Safe work environment High governance standards and effective structures Diversity, equity, and inclusion Stakeholders‘ engagement Animal welfare and bioethics Our Patients Our Values
Slide 28: Sustainability at Evotec
Sustainability at Evotec Selected ESG-KPIs 33% 32% 75% 25% Evotec SE Share of PhDs Women in Leadership Peers without ´ Peers with SBTi targets SBTi targets EcoVadis Score 46% 93 52% Men 39% Evotec: 60 ~5,000x talent Nationalities 4% 5% 0% 54% 0-25 25-45 45-65 65-85 85-100 Women PAGE 28 Derived from
Slide 29: EVOequity portfolio making progress
EVOequity portfolio making progress Operational VC model – diversified portfolio with multiple shots on goal At Equity Holding (≥20%) or significant influence • Breakpoint Therapeutics – Nomination of first preclinical development candidate, BTX-011 • Tubulis – Closing of upsized € 128 m Series B2 fi
Slide 30: Shareholders supporting sustainable growth
Shareholders supporting sustainable growth Shareholder structure1 ~ 8% Novo Holdings A/S ~ 7% Mubadala Investment Company ~ 10% T. Rowe Price Group ~ 75% Free float Number of shares: Listings: 52 week high/low: 177.5 m Frankfurt Stock Exchange (MDAX, TecDAX), Ticker: EVT € 23.44/€ 5.06 NASDAQ Global
Slide 31: Volker Braun, Investor Relations & ESG
Volker Braun EVP Global Head of Investor Relations & ESG +49 (0) 40 228 999 338 (direct) +49 (0) 151 1940 5058 (mobile) volker.braun@evotec.com